3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 1
1
Status
Completed
2
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
1
Multiple Myeloma
1
Interventions
anlotinib
5
Cisplatin
5
Carboplatin
5
Immune Checkpoint Inhibitors
4
tislelizumab
3
sintilimab
3
lenvatinib
3
Oxaliplatin
3
Fluorouracil
3
Capecitabine
3
Bevacizumab
3
venetoclax
2
Rosuvastatin Calcium
2
Prednisone
2
Megestrol Acetate
2
Leucovorin
2
Gemcitabine
2
Drug Therapy
2
Dexmedetomidine
2
Dexamethasone
2
Aspirin
2
zanubrutinib
1
xiaojin wan
1
trastuzumab deruxtecan
1
trametinib
1
toripalimab
1
tocilizumab
1
testosterone 17 beta-cypionate
1
tenofovir alafenamide
1
telitacicept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Not yet recruiting
×
ibrutinib
×
Clear all
NCT07474961
2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4
Not yet recruiting
400 enrolled